+关注
丛羽
暂无个人介绍
IP属地：河北
17
关注
0
粉丝
0
主题
0
勋章
主贴
热门
丛羽
2022-08-15
充值了吧
中金：维持同仁堂国药(03613)“跑赢行业”评级 目标价降至12.5港元
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4106871737810020,"uuid":"4106871737810020","gmtCreate":1643768668725,"gmtModify":1643768668725,"name":"丛羽","pinyin":"cycongyu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","hatId":"ca_profile_frame_Mpy1eK","hatName":"","vip":1,"status":2,"fanSize":0,"headSize":17,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":4,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"1f74612b6f95455f970edd02b5316db8-4","templateUuid":"1f74612b6f95455f970edd02b5316db8","name":"收益排行","description":"Top 10%","bigImgUrl":"https://static.tigerbbs.com/15d4b5a89fa218ed3a35da1a05874cf6","smallImgUrl":"https://static.tigerbbs.com/16e2b28d75d7746886400fad4f4ec3e3","grayImgUrl":"https://static.tigerbbs.com/6f578d36f80e1a3d9c705f395e522048","redirectLinkEnabled":1,"redirectLink":"https://www.itigerup.com/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5300},{"badgeId":"5697d37f217342faaa027fdb5a6e7c12-6","templateUuid":"5697d37f217342faaa027fdb5a6e7c12","name":"单笔平均盈利排行","description":"Top 3%","bigImgUrl":"https://static.tigerbbs.com/a598d1c237f4abca28b7dec180a69b90","smallImgUrl":"https://static.tigerbbs.com/6b82de83729a6fa0c5bd4e93dcee29be","grayImgUrl":"https://static.tigerbbs.com/b7430ddcdaa39bc9a65efade13881001","redirectLinkEnabled":1,"redirectLink":"https://www.itigerup.com/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5200},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.25","exceedPercentage":"60.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.11","exceedPercentage":"60.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":7,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.11","exceedPercentage":"60.89%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"河北","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":684575687,"gmtCreate":1660528669453,"gmtModify":1660528988240,"author":{"id":"4106871737810020","authorId":"4106871737810020","name":"丛羽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"充值了吧","listText":"充值了吧","text":"充值了吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/684575687","repostId":"2259064777","repostType":2,"repost":{"id":"2259064777","pubTimestamp":1660525624,"share":"https://www.laohu8.com/m/news/2259064777?lang=&edition=full","pubTime":"2022-08-15 09:07","market":"sh","language":"zh","title":"中金：维持同仁堂国药(03613)“跑赢行业”评级 目标价降至12.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2259064777","media":"智通财经","summary":"智通财经APP获悉，中金发布研究报告称，维持同仁堂国药“跑赢行业”评级，下调2022/23年净利润预测15.9%/18.7%至5.78/6.35亿港元，目标价下调15%至12.5港元，较当前股价有30.6%的上行空间。公司披露今年上半年业绩，收入6.26亿港元，归母净利润2.15亿港元，对应每股盈利0.26港元，符合该行预期。2022年上半年毛利率同比下降2个百分点至69.1%，销售和管理费用率同比增加1.2个百分点，营业利润率同比减少2.7个百分点至46.6%，营业利润同比减少16%至2.92亿港元。","content":"<html><body><p>智通财经APP获悉，中金发布研究报告称，维持<a href=\"https://laohu8.com/S/08138\">同仁堂国药</a>(03613)“跑赢行业”评级，下调2022/23年净利润预测15.9%/18.7%至5.78/6.35亿港元，目标价下调15%至12.5港元，较当前股价有30.6%的上行空间。公司披露今年上半年业绩，收入6.26亿港元，归母净利润2.15亿港元，对应每股盈利0.26港元，符合该行预期。</p><p>报告中称，分市场看，公司2022年上半年香港市场收入同比增加4%至3.1亿港元;内地市场收入同比下降57.1%至0.7亿港元;海外市场收入同比增加1.1%至2.47亿港元。该行认为随着疫情逐渐稳定，主营业务下半年有望逐渐恢复，且预计新产品灵芝<a href=\"https://laohu8.com/S/LOHA\">乐活</a>胶囊有望推出市场。2022年上半年毛利率同比下降2个百分点至69.1%，销售和管理费用率同比增加1.2个百分点，营业利润率同比减少2.7个百分点至46.6%，营业利润同比减少16%至2.92亿港元。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中金：维持同仁堂国药(03613)“跑赢行业”评级 目标价降至12.5港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中金：维持同仁堂国药(03613)“跑赢行业”评级 目标价降至12.5港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-15 09:07 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/771105.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中金发布研究报告称，维持同仁堂国药(03613)“跑赢行业”评级，下调2022/23年净利润预测15.9%/18.7%至5.78/6.35亿港元，目标价下调15%至12.5港元，较当前股价有30.6%的上行空间。公司披露今年上半年业绩，收入6.26亿港元，归母净利润2.15亿港元，对应每股盈利0.26港元，符合该行预期。报告中称，分市场看，公司2022年上半年香港市场收入...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/771105.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03613":"同仁堂国药"},"source_url":"http://www.zhitongcaijing.com/content/detail/771105.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2259064777","content_text":"智通财经APP获悉，中金发布研究报告称，维持同仁堂国药(03613)“跑赢行业”评级，下调2022/23年净利润预测15.9%/18.7%至5.78/6.35亿港元，目标价下调15%至12.5港元，较当前股价有30.6%的上行空间。公司披露今年上半年业绩，收入6.26亿港元，归母净利润2.15亿港元，对应每股盈利0.26港元，符合该行预期。报告中称，分市场看，公司2022年上半年香港市场收入同比增加4%至3.1亿港元;内地市场收入同比下降57.1%至0.7亿港元;海外市场收入同比增加1.1%至2.47亿港元。该行认为随着疫情逐渐稳定，主营业务下半年有望逐渐恢复，且预计新产品灵芝乐活胶囊有望推出市场。2022年上半年毛利率同比下降2个百分点至69.1%，销售和管理费用率同比增加1.2个百分点，营业利润率同比减少2.7个百分点至46.6%，营业利润同比减少16%至2.92亿港元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":684575687,"gmtCreate":1660528669453,"gmtModify":1660528988240,"author":{"id":"4106871737810020","authorId":"4106871737810020","name":"丛羽","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"充值了吧","listText":"充值了吧","text":"充值了吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/684575687","repostId":"2259064777","repostType":2,"repost":{"id":"2259064777","pubTimestamp":1660525624,"share":"https://www.laohu8.com/m/news/2259064777?lang=&edition=full","pubTime":"2022-08-15 09:07","market":"sh","language":"zh","title":"中金：维持同仁堂国药(03613)“跑赢行业”评级 目标价降至12.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2259064777","media":"智通财经","summary":"智通财经APP获悉，中金发布研究报告称，维持同仁堂国药“跑赢行业”评级，下调2022/23年净利润预测15.9%/18.7%至5.78/6.35亿港元，目标价下调15%至12.5港元，较当前股价有30.6%的上行空间。公司披露今年上半年业绩，收入6.26亿港元，归母净利润2.15亿港元，对应每股盈利0.26港元，符合该行预期。2022年上半年毛利率同比下降2个百分点至69.1%，销售和管理费用率同比增加1.2个百分点，营业利润率同比减少2.7个百分点至46.6%，营业利润同比减少16%至2.92亿港元。","content":"<html><body><p>智通财经APP获悉，中金发布研究报告称，维持<a href=\"https://laohu8.com/S/08138\">同仁堂国药</a>(03613)“跑赢行业”评级，下调2022/23年净利润预测15.9%/18.7%至5.78/6.35亿港元，目标价下调15%至12.5港元，较当前股价有30.6%的上行空间。公司披露今年上半年业绩，收入6.26亿港元，归母净利润2.15亿港元，对应每股盈利0.26港元，符合该行预期。</p><p>报告中称，分市场看，公司2022年上半年香港市场收入同比增加4%至3.1亿港元;内地市场收入同比下降57.1%至0.7亿港元;海外市场收入同比增加1.1%至2.47亿港元。该行认为随着疫情逐渐稳定，主营业务下半年有望逐渐恢复，且预计新产品灵芝<a href=\"https://laohu8.com/S/LOHA\">乐活</a>胶囊有望推出市场。2022年上半年毛利率同比下降2个百分点至69.1%，销售和管理费用率同比增加1.2个百分点，营业利润率同比减少2.7个百分点至46.6%，营业利润同比减少16%至2.92亿港元。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中金：维持同仁堂国药(03613)“跑赢行业”评级 目标价降至12.5港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中金：维持同仁堂国药(03613)“跑赢行业”评级 目标价降至12.5港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-15 09:07 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/771105.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中金发布研究报告称，维持同仁堂国药(03613)“跑赢行业”评级，下调2022/23年净利润预测15.9%/18.7%至5.78/6.35亿港元，目标价下调15%至12.5港元，较当前股价有30.6%的上行空间。公司披露今年上半年业绩，收入6.26亿港元，归母净利润2.15亿港元，对应每股盈利0.26港元，符合该行预期。报告中称，分市场看，公司2022年上半年香港市场收入...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/771105.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03613":"同仁堂国药"},"source_url":"http://www.zhitongcaijing.com/content/detail/771105.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2259064777","content_text":"智通财经APP获悉，中金发布研究报告称，维持同仁堂国药(03613)“跑赢行业”评级，下调2022/23年净利润预测15.9%/18.7%至5.78/6.35亿港元，目标价下调15%至12.5港元，较当前股价有30.6%的上行空间。公司披露今年上半年业绩，收入6.26亿港元，归母净利润2.15亿港元，对应每股盈利0.26港元，符合该行预期。报告中称，分市场看，公司2022年上半年香港市场收入同比增加4%至3.1亿港元;内地市场收入同比下降57.1%至0.7亿港元;海外市场收入同比增加1.1%至2.47亿港元。该行认为随着疫情逐渐稳定，主营业务下半年有望逐渐恢复，且预计新产品灵芝乐活胶囊有望推出市场。2022年上半年毛利率同比下降2个百分点至69.1%，销售和管理费用率同比增加1.2个百分点，营业利润率同比减少2.7个百分点至46.6%，营业利润同比减少16%至2.92亿港元。","news_type":1},"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
